Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum MPX International Corp C.MPXI

Alternate Symbol(s):  MPXOF

MPX International Corporation is a Canada-based multinational diversified cannabis company. The Company is focused on developing and operating assets across the international cannabis industry with an emphasis on cultivating, manufacturing and marketing products, which include cannabinoids as their primary active ingredient. The Company operates through three segments: Canada, Europe / Africa... see more

CSE:MPXI - Post Discussion

MPX International Corp > C.MPXI Harvested 30 tonnes of high-CBD cannabis flower.
View:
Post by bogdansz on Dec 03, 2019 9:03pm

C.MPXI Harvested 30 tonnes of high-CBD cannabis flower.

Another Cannabis Manufacturing Licence Awarded In Australia November 8, 2019 MPX Australia cannabis licence MPX International Corporation says its Australian subsidiary has been awarded a Cannabis Manufacture Licence by the nations Office of Drug Control. The licence was granted to MPX Australia Pty Ltd, which according to ASIC records was registered here just last year; with its registered office located in Melbourne, Victoria. In July this year, MPX International announced the purchase of the remaining stake in MPX Australia that it did not already own. The company has commenced work on a facility in Launceston, Tasmania that should be starting commercial production in the middle of next year, assuming it receives final regulatory approvals. MPX says it has leased a 6,500 square metre building that will house indoor cultivation, extraction and manufacturing of medicinal cannabis products. MPX notes it employs high-capacity supercritical CO2 and ethanol for cannabinoid extraction processes. The as yet unspecified products made at the facility will be supplied to Australias domestic market, and MPX has its eye on export to the wider Oceania and Asia-Pacific region in the future. The Launceston venture will also act as a tissue culture and genetics research facility providing clone supply, and advancing quality of products and efficiency of extraction for MPX Internationals global operations. We chose Australia, and specifically the island state of Tasmania, because of its reputation for producing high quality organic products using clean energy, the availability of qualified technical staff, and the positive support from local government, said MPX International Chairman, President and CEO W. Scott Boyes. According to its web site, MPX International Corporation (CSE:MPXI; OTC PINK:MPXOF) evolved out MPX Bioceutical, which was founded in 2015. MPX International was incorporated in its home country of Canada last year and became a public company in February this year. It currently has six brands in its stable and claims an annual production capacity of 8.85 tonnes. Last year it harvested 30 tonnes of high-CBD cannabis flower. Aside from Australia and North America, the company also has presences in South Africa, Switzerland, Malta and the United Kingdom.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities